Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Other Non-Current Assets (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Other Non-Current Assets for 4 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 29.62% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, down 29.62% year-over-year, with the annual reading at $1.4 million for FY2025, 29.62% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $1.4 million at Centessa Pharmaceuticals, down from $1.6 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $6.0 million in Q1 2023, with the low at $619000.0 in Q1 2022.
  • Average Other Non-Current Assets over 4 years is $2.1 million, with a median of $1.9 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets soared 875.77% in 2023, then plummeted 68.82% in 2024.
  • Over 4 years, Other Non-Current Assets stood at $1.9 million in 2022, then skyrocketed by 35.85% to $2.6 million in 2023, then dropped by 19.89% to $2.0 million in 2024, then decreased by 29.62% to $1.4 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $1.4 million, $1.6 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.